Clinical Medicine and Pharmacology Clinical Medicine and Pharmacology Клиническая медицина и фармакология 2409-3750 73891 10.12737/2409-3750-2024-9-4-8-13 Обзоры reviews Обзоры Genetically engineered biological drugs in therapeutic practice Генно-инженерные биологические препараты в терапевтической практике Долгополов М. С. Dolgopolov M. S. Тульский государственный университет Tula State University 30 01 2024 30 01 2024 9 4 8 13 30 01 2024 https://zh-szf.ru/en/nauka/article/73891/view

Терапия генно-инженерными биологическими препаратами – это новый подход к лечению аутоиммунных и аллергических заболеваний в пульмонологии, гематологии, гастроэнтерологии, неврологии, онкологии. Сегодня благодаря им удается кардинально улучшить качество жизни пациентов с такими заболеваниями, которые раньше считались неизлечимыми и плохо контролировались. В ряде случаев применение терапии позволяет достигать длительной и стойкой ремиссии. В статье рассмотрен ряд генно-инженерных биологических препаратов, используемых в различных терапевтических направлениях и механизмы их действия.

Therapy with genetically engineered biological drugs is a new approach to the treatment of autoimmune and allergic diseases in pulmonology, hematology, gastroenterology, neurology, and oncology. Today, thanks to them, it is possible to radically improve the quality of life of patients with diseases that were previously considered incurable and poorly controlled. In some cases, the use of therapy can achieve long-term and stable remission. The article provides an overview of genetically engineered biological drugs used in various therapeutic areas and the mechanisms of their action.

 генно-инженерные биологические препараты бронхиальная астма омализумаб квилизумаб лигелизумаб лебрикизумаб тралокинумаб дупилумаб меполизумаб бенрализумаб февипипрант genetically engineered biological drugs bronchial asthma omalizumab omalizumab omalizumab lebrikizumab tralokinumab dupilumab mepolizumab benralizumab fevipiprant.

Зырянов С.К., Бутранова О.И. Генно-инженерно-биологические препараты в терапии бронхиальной астмы: современные достижения. Пульмонология. 2018; 28 Zyryanov S.K., Butranova O.I. Genno-inzhenerno-biologicheskie preparaty v terapii bronhial'noy astmy: sovremennye dostizheniya. Pul'monologiya. 2018; 28 Menzella F., Galeone C., Bertolini F. et al. Innovative treat-ments for severe refractory asthma: how to choose the right option for the right patient? J. Asthma Allergy. 2017; Menzella F., Galeone C., Bertolini F. et al. Innovative treat-ments for severe refractory asthma: how to choose the right option for the right patient? J. Asthma Allergy. 2017; Oettgen H.C. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J. Allergy Clin. Immunol. 2016; 137 Oettgen H.C. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J. Allergy Clin. Immunol. 2016; 137 Braunstahl G.J., Chen C.W., Maykut R. et al. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir. Med. 2013; 107. Braunstahl G.J., Chen C.W., Maykut R. et al. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir. Med. 2013; 107. Harris J.M., Maciuca R., Bradley M.S. et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir. Res. 2016; Harris J.M., Maciuca R., Bradley M.S. et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir. Res. 2016; Gauvreau G.M., Arm J.P., Boulet L.P. et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J. Allergy Clin. Immunol. 2016; 138 Gauvreau G.M., Arm J.P., Boulet L.P. et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J. Allergy Clin. Immunol. 2016; 138 Hanania N.A., Noonan M., Corren J. et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015; 70 Hanania N.A., Noonan M., Corren J. et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015; 70 Scheerens H., Arron J.R., Zheng Y. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin. Exp. Allergy. 2014; 44 Scheerens H., Arron J.R., Zheng Y. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin. Exp. Allergy. 2014; 44 Hanania N.A, Korenblat P., Chapman K.R. et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 2016; 4 Hanania N.A, Korenblat P., Chapman K.R. et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 2016; 4 Panettieri R.A. Jr, Wang M., Braddock M. et al. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018; 10 Panettieri R.A. Jr, Wang M., Braddock M. et al. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018; 10 Slager R.E., Otulana B.A., Hawkins G.A. et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J. Allergy Clin. Immunol. 2012; 130 Slager R.E., Otulana B.A., Hawkins G.A. et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J. Allergy Clin. Immunol. 2012; 130 Shirley M. Dupilumab: First Global Approval. Drugs. 2017; 77 Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 Shirley M. Dupilumab: First Global Approval. Drugs. 2017; 77 Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371 Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371 Varricchi G., Bagnasco D., Ferrando M. et al. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther. Adv. Respir. Dis. 2017; 11 Varricchi G., Bagnasco D., Ferrando M. et al. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther. Adv. Respir. Dis. 2017; 11 Pelaia C., Vatrella A., Bruni A. et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des. Devel. Ther. 2018; 12 Pelaia C., Vatrella A., Bruni A. et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des. Devel. Ther. 2018; 12 Erpenbeck V.J., Popov T.A., Miller D. et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm. Pharmacol. Ther. 2016 Erpenbeck V.J., Popov T.A., Miller D. et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm. Pharmacol. Ther. 2016 Kang-Moon Lee, Yoon Tae Jeen, Ju Yeon Cho, Chang Kyun Lee, Ja-Seol Koo, Dong Il Park, Jong Pil Im, Soo Jung Park, You Sun Kim, Tae Oh Kim, Suck-Ho Lee, Byung Ik Jang, Ji Won Kim, Young Sook Park, Eun-Soo Kim, Chang Hwan Choi, Hyo Jong Kim. Efficacy, Safety, and Predictors of Response to Infliximab Therapy for Ulcerative Colitis.A Korean Multicenter Retrospective Study.J Gastroenterol Hepatol. 2013;28(12):1829-1833. Kang-Moon Lee, Yoon Tae Jeen, Ju Yeon Cho, Chang Kyun Lee, Ja-Seol Koo, Dong Il Park, Jong Pil Im, Soo Jung Park, You Sun Kim, Tae Oh Kim, Suck-Ho Lee, Byung Ik Jang, Ji Won Kim, Young Sook Park, Eun-Soo Kim, Chang Hwan Choi, Hyo Jong Kim. Efficacy, Safety, and Predictors of Response to Infliximab Therapy for Ulcerative Colitis.A Korean Multicenter Retrospective Study.J Gastroenterol Hepatol. 2013;28(12):1829-1833. Sartor RB, Hoentjen F. Proinflammatory cytokines and signaling pathways in intestinal innate immune cells. Mucosal Immunology. 2005;30:681-701. Sartor RB, Hoentjen F. Proinflammatory cytokines and signaling pathways in intestinal innate immune cells. Mucosal Immunology. 2005;30:681-701. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333 Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333 Harousseau JL. Interet clinique de l'interferon alpha dans le traitement des hemopathies malignes.Presse Med 1997; 26: 857 - 9. Harousseau JL. Interet clinique de l'interferon alpha dans le traitement des hemopathies malignes.Presse Med 1997; 26: 857 - 9. Kieseier BC. The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis. CNS Drugs. 2011;25 Kieseier BC. The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis. CNS Drugs. 2011;25 Francis G, Kappos L, O’Connor P, Collins W, Tang D, Mercier F, Cohen JA. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler J. 2014;20 Francis G, Kappos L, O’Connor P, Collins W, Tang D, Mercier F, Cohen JA. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler J. 2014;20 Immune system resetting and long-term remission in multiple sclerosis: rationale and possibilities an EXCEMED Satellite Symposium at the 3rd EAN Congress/EXCEMED [Электронный ресурс]. Дата обращения: 25.12.18. URL: https://www.excemed.org/live-events/immune-systemresetting-and-long-term-remission-multiple-sclerosis-rationale-andpossibilities-excemed-satellite-symposium-3rd-ean-congress Immune system resetting and long-term remission in multiple sclerosis: rationale and possibilities an EXCEMED Satellite Symposium at the 3rd EAN Congress/EXCEMED [Elektronnyy resurs]. Data obrascheniya: 25.12.18. URL: https://www.excemed.org/live-events/immune-systemresetting-and-long-term-remission-multiple-sclerosis-rationale-andpossibilities-excemed-satellite-symposium-3rd-ean-congress Wiendl H, Bourdette D, Ciccarelli O. Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis? Neurology. 2017;89 11 Wiendl H, Bourdette D, Ciccarelli O. Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis? Neurology. 2017;89 11 Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2) Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2) McCall B. Alemtuzumab to be restricted pending review, says EMA. Lancet. 2019;393(10182):1683. https://doi.org/10.1016/S0140-6736(19)30935-3 McCall B. Alemtuzumab to be restricted pending review, says EMA. Lancet. 2019;393(10182):1683. https://doi.org/10.1016/S0140-6736(19)30935-3 Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28-35. https://doi.org/10.1097/WNF.0b013e318204cd90 Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28-35. https://doi.org/10.1097/WNF.0b013e318204cd90 Саллес Г. И др. Ритуксимаб при В-клеточных гематологических злокачественных новообразованиях: обзор 20-летнего клинического опыта.Adv.2017 PMID 28983798 Salles G. I dr. Rituksimab pri V-kletochnyh gematologicheskih zlokachestvennyh novoobrazovaniyah: obzor 20-letnego klinicheskogo opyta.Adv.2017 PMID 28983798 Тарасова Л.В., Бусалаева Е.И., Цыганова Ю.В., Жудылина Н.В., Матысякевич И.Д. Опыт применения ведолизумаба при язвенном колите (клинический случай). Доказательная гастроэнтерология. 2020;9(3):77-82. https://doi.org/10.17116/dokgastro2020903177 Tarasova L.V., Busalaeva E.I., Cyganova Yu.V., Zhudylina N.V., Matysyakevich I.D. Opyt primeneniya vedolizumaba pri yazvennom kolite (klinicheskiy sluchay). Dokazatel'naya gastroenterologiya. 2020;9(3):77-82. https://doi.org/10.17116/dokgastro2020903177